Bitcoin price today: falls to 2-week low below $113k ahead of Fed Jackson Hole
Edwards Lifesciences (NYSE:EW) Global President of TAVR & Surg, Larry L Wood, sold 8,950 shares of company stock on August 18, 2025, for approximately $698,679. The sales were executed at a weighted average price of $78.0647, with individual prices ranging from $77.68 to $78.43.
On the same day, Wood also exercised options to acquire 8,950 shares of Edwards Lifesciences common stock at a price of $59.2567, for a total value of $530,347. These options stemmed from an employee stock option plan and were exercised on August 18th, 2025.
These transactions were executed under a pre-arranged Rule 10b5-1 trading plan adopted by Wood on February 27, 2025. Want deeper insights into Edwards Lifesciences’ valuation and growth prospects? InvestingPro offers exclusive access to 12+ additional ProTips and comprehensive financial analysis. Following the sale, Wood directly owns 206,900.3913 shares of Edwards Lifesciences. He also indirectly owns 148.1703 shares through a 401(k).
In other recent news, Edwards Lifesciences reported strong second-quarter results, surpassing expectations for both revenue and earnings. The company’s Transcatheter Aortic Valve Replacement (TAVR) segment showed a 7.8% year-over-year growth, excluding foreign exchange impacts, with robust performance in both domestic and international markets. This positive performance led UBS and Bernstein to raise their price targets for Edwards Lifesciences to $85, while Piper Sandler increased its target to $90, maintaining an Overweight rating. Additionally, BTIG upgraded the stock to Buy, citing improved stability in the TAVR segment, which is projected to grow 6-7% year-over-year by 2025 on a constant currency basis.
Moody’s also revised the company’s outlook to positive from stable, affirming its Baa2 ratings. The credit rating agency highlighted Edwards Lifesciences’ leadership in medical devices for structural heart diseases and its promising growth opportunities in transcatheter mitral and tricuspid therapies. These developments reflect analysts’ confidence in the company’s future prospects and its ability to maintain its market position despite increasing competition.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.